Avalon GloboCare Corp. reported its financial results for the third quarter and the first nine months of 2025, revealing a net loss of $254,268 for the three months ended September 30, 2025, a significant decrease from the $1,679,200 loss recorded in the same period of 2024. For the nine months ended September 30, 2025, the company experienced a net loss of $16,194,977, compared to a loss of $5,178,739 for the same period in 2024. The decrease in quarterly losses was attributed to improved real property rental income and a credit loss recovery of $1,650,000, while the increase in the nine-month loss was primarily due to a loss on extinguishment of debt amounting to $9,076,587.
In terms of revenue, Avalon GloboCare generated $350,099 in real property rental revenue for the third quarter of 2025, a slight increase of 1.4% from $345,159 in the prior year. For the nine-month period, rental revenue rose to $1,050,305, up 6.3% from $987,634 in 2024. The company attributed this growth to an increase in the number of tenants occupying its New Jersey property. Operating expenses for real property also decreased, with third-quarter expenses falling to $234,366 from $245,528 a year earlier, reflecting a focus on cost management.
Significant operational changes included the cessation of laboratory services following the redemption of a 40% equity interest in Lab Services MSO in February 2025. This strategic decision was made to preserve cash and refocus efforts on the company's core business of real estate and the commercialization of its KetoAir™ breathalyzer device. The company has also been actively pursuing additional financing options to support its operations, as indicated by a working capital deficit of approximately $11.5 million as of September 30, 2025.
Avalon GloboCare's total assets decreased to $9.1 million as of September 30, 2025, down from $21 million at the end of 2024, primarily due to the reduction in cash and the write-off of the equity method investment. The company’s cash balance at the end of the third quarter was approximately $334,000, a decline of over $2.5 million from the previous year. The company is currently exploring various avenues for raising capital, including equity sales, to ensure it can meet its operational needs and continue its business activities.
Looking ahead, Avalon GloboCare's management expressed uncertainty regarding the company's ability to continue as a going concern, emphasizing the need for additional capital to fund operations and meet obligations. The company plans to focus on generating revenue from its real estate holdings and the KetoAir product while navigating the challenges posed by its current financial situation.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. develops and markets precision diagnostic consumer products, primarily the KetoAir breathalyzer, which measures ketosis levels to support diabetic and ketogenic diet management. The company previously offered laboratory testing services but has since exited that segment. It operates mainly in the U.S. market, leveraging FDA-cleared medical device technology combined with AI-driven nutrition software, targeting health-conscious consumers through direct online sales and digital marketing channels.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.